Aquestive Therapeutics Files 8-K

Ticker: AQST · Form: 8-K · Filed: Nov 6, 2024 · CIK: 1398733

Aquestive Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAquestive Therapeutics, Inc. (AQST)
Form Type8-K
Filed DateNov 6, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, regulation-fd

Related Tickers: AQST

TL;DR

AQST filed an 8-K on Nov 6, 2024, updating corporate info & filings.

AI Summary

Aquestive Therapeutics, Inc. filed an 8-K on November 6, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 30 Technology Drive, Warren, NJ 07059, with a principal business phone number of 908-941-1900. The company was formerly known as MonoSol Rx, Inc., with a name change effective May 7, 2007.

Why It Matters

This 8-K filing serves as an official notification to the SEC and the public regarding Aquestive Therapeutics' corporate and financial reporting status.

Risk Assessment

Risk Level: low — This filing is routine corporate disclosure and does not contain material non-public information that would inherently increase risk.

Key Players & Entities

  • Aquestive Therapeutics, Inc. (company) — Registrant
  • November 6, 2024 (date) — Date of Report
  • 30 Technology Drive, Warren, NJ 07059 (location) — Principal Executive Offices
  • 908-941-1900 (phone_number) — Principal Business Phone
  • MonoSol Rx, Inc. (company) — Former Company Name
  • May 7, 2007 (date) — Date of Name Change

FAQ

What is the primary purpose of this Form 8-K filing?

The primary purpose of this Form 8-K filing is to report a Regulation FD Disclosure and Financial Statements and Exhibits.

What is the principal executive office address for Aquestive Therapeutics, Inc.?

The principal executive office address is 30 Technology Drive, Warren, NJ 07059.

What is the telephone number for Aquestive Therapeutics, Inc.'s principal executive offices?

The telephone number is (908) 941-1900.

What was Aquestive Therapeutics, Inc.'s former company name?

The former company name was MonoSol Rx, Inc.

When was the name change from MonoSol Rx, Inc. to Aquestive Therapeutics, Inc. effective?

The name change was effective on May 7, 2007.

Filing Stats: 589 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-11-06 16:01:33

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I

Filing Documents

01

Item 7.01 Regulation FD Disclosure. Aquestive Therapeutics, Inc. (the "Company") is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means. A copy of the Company's investor presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The investor presentation is available on the Events and Presentations Page of the Investors section of the Company's website located at www.aquestive.com, although the Company reserves the right to discontinue that availability at any time. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of, Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description 99.1 Aquestive Therapeutics, Inc. Corporate Presentation dated November 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 6, 2024 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.